12:00 AM
 | 
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cinryze regulatory update

Health Canada granted Priority Review to an NDS from ViroPharma for Cinryze for the treatment and pre-procedure and routine prevention of angioedema attacks in hereditary angioedema (HAE) patients ages 6 years and older. ViroPharma...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >